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Abstract
Aging	leads	to	skeletal	muscle	atrophy	(i.e.,	sarcopenia),	and	muscle	fiber	loss	is	a	criti‐
cal component of this process. The mechanisms underlying these age‐related changes, 
however,	remain	unclear.	We	show	here	that	mTORC1	signaling	is	activated	in	a	subset	
of skeletal muscle fibers in aging mouse and human, colocalized with fiber damage. 
Activation	of	mTORC1	in	TSC1	knockout	mouse	muscle	fibers	increases	the	content	of	
morphologically abnormal mitochondria and causes progressive oxidative stress, fiber 
damage, and fiber loss over the lifespan. Transcriptomic profiling reveals that mTORC1’s 
activation	 increases	 the	expression	of	growth	differentiation	 factors	 (GDF3,	5,	and	
15),	and	of	genes	involved	in	mitochondrial	oxidative	stress	and	catabolism.	We	show	
that	increased	GDF15	is	sufficient	to	induce	oxidative	stress	and	catabolic	changes,	
and	that	mTORC1	increases	the	expression	of	GDF15	via	phosphorylation	of	STAT3.	
Inhibition	of	mTORC1	in	aging	mouse	decreases	the	expression	of	GDFs	and	STAT3’s	
phosphorylation in skeletal muscle, reducing oxidative stress and muscle fiber damage 
and loss. Thus, chronically increased mTORC1 activity contributes to age‐related mus‐
cle	atrophy,	and	GDF	signaling	is	a	proposed	mechanism.
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1  | INTRODUC TION
Age‐dependent	 loss	of	 skeletal	muscle	mass	 and	 function,	 that	 is,	
sarcopenia, is an increasingly significant public health concern as av‐
erage life expectancy increases. Degeneration in muscle structure 
and function during aging increases frailty, disability, metabolic dis‐
orders,	and	mortality	in	the	elderly	population	(Evans	et	al.,	2010).	
It is thus central to the aging process. Numerous changes in aging 
skeletal muscle have been reported, including muscle fiber loss and 
induction of pathological regeneration reflected by centrally lo‐
cated	myonuclei	(Larsson,	Sjödin,	&	Karlsson,	1978;	Marzetti,	Lees,	
Wohlgemuth,	 &	 Leeuwenburgh,	 2009;	 Narici	 &	 Maffulli,	 2010).	
Mitochondria are significantly altered in aged skeletal muscle, where 
they	 are	 more	 abundant	 but	 with	 reduced	 function	 (Short	 et	 al.,	
2005),	 morphologically	 abnormal,	 and	 more	 variable	 in	 size,	 with	
the	appearance	of	enlarged	and	giant	mitochondria	 (Arking,	2006;	
Demontis,	Piccirillo,	Goldberg,	&	Perrimon,	2013;	Miller	et	al.,	2008;	
Murakoshi,	Osamura,	&	Watanabe,	1985;	Tandler	&	Hoppel,	1986).	
Dysfunctional mitochondria in muscle fibers may underlie apoptosis 
and necrosis, which likely plays a considerable role in aging muscle 
fiber	loss	(Cheema,	Herbst,	McKenzie,	&	Aiken,	2015).	All	of	these	
changes likely result in increased muscle fatigability and decreased 
force generation. The etiology of these age‐dependent deleterious 
changes and ultimate fiber loss in skeletal muscle, however, remains 
largely unclear.
The mechanistic target of rapamycin, mTOR, is an evolution‐
arily conserved serine–threonine protein kinase which is generally 
thought to promote various anabolic cellular processes in response 
to	growth	factors,	nutrients,	and	stress	(Inoki,	Corradetti,	&	Guan,	
2005;	 Sabatini,	 2017;	 Saxton	 &	 Sabatini,	 2017).	 mTOR	 exists	 in	
two distinct complexes, mTORC1 and mTORC2, and the former is 
directly and sensitively inhibited by rapamycin. The tuberous scle‐
rosis	complex	(TSC)	1	and	TSC2	tumor	suppressors	are	major	nega‐
tive regulators of mTORC1. Mutation in either TSC1 or TSC2 leads 
to	 constitutive	 activation	 of	mTORC1.	Activated	mTORC1	phos‐
phorylates	downstream	targets,	for	example,	S6	kinase	and	eIF4E	
binding proteins, and S6 kinase further phosphorylates ribosomal 
S6 protein, facilitating protein synthesis. The level of phosphor‐
ylated S6 protein is often used to probe the activity of mTORC1 
signaling. mTORC1 regulates developmental muscle growth, and 
Akt‐dependent	 activation	 of	 mTORC1	 is	 positively	 associated	
with	muscle	mass.	For	instance,	inhibition	of	mTORC1	through	ei‐
ther	 deletion	 of	 the	mTORC1	 component,	 raptor	 (Bentzinger	 et	
al.,	 2008),	 or	 overexpression	 of	 the	 mTORC1	 suppressor,	 TSC1	
(Wan	et	al.,	2006),	causes	muscle	atrophy.	In	contrast,	activation	
of	 mTORC1	 by	 overexpression	 of	 constitutively	 active	 Akt,	 an	
mTORC1	upstream	activator,	induces	muscle	hypertrophy	(Bodine	
et	 al.,	 2001).	 However,	 Akt‐independent	 activation	 of	 mTORC1	
leads	 to	 protein	 degradation	 and	muscle	 atrophy	 (Bentzinger	 et	
al.,	 2013;	 Castets	 et	 al.,	 2013;	 Tang	 et	 al.,	 2014),	 likely	 through	
feedback	inhibition	of	Akt	and	the	consequent	activation	of	FoxO	
(Tang	et	al.,	2014).	Beyond	this	dual	function	of	mTORC1	in	pro‐
teostasis, activated mTORC1 also regulates metabolism by induc‐
tion	of	FGF21	(Cornu	et	al.,	2014;	Guridi	et	al.,	2015)	and	regulates	
mitochondrial	function,	including	oxygen	consumption	(Schieke	et	
al.,	2006)	and	oxidative	function	(Cunningham	et	al.,	2007),	in	cul‐
tured cells. It was reported that the activities of mTORC1 and its 
downstream	S6	kinase	are	induced	in	aged	skeletal	muscle	(Baar,	
Carbajal,	Ong,	&	Lamming,	2016;	Houtkooper	et	al.,	2011;	Kimball	
&	 Jefferson,	 2004;	Markofski	 et	 al.,	 2015).	However,	 the	 down‐
stream effects of the activated mTORC1 in aging skeletal muscle 
remain unknown.
Growth	differentiation	factors	(GDFs)	are	subgroup	members	in	
the	TGF‐β	(transforming	growth	factor	beta)	superfamily	that	func‐
tion	predominantly	 in	regulating	development.	For	example,	GDF3	
and	GDF5	 are	 involved	 in	 bone	 formation	 in	 early	 embryonic	 de‐
velopment	(Buxton,	Edwards,	Archer,	&	Francis‐West,	2001;	Levine	
&	 Brivanlou,	 2006).	 GDF8/myostatin	 negatively	 regulates	 muscle	
growth	 (McPherron,	 Lawler,	 &	 Lee,	 1997).	 GDF15,	 also	 known	 as	
macrophage	 inhibitory	 cytokine	 1	 (MIC‐1)	 or	 nonsteroidal	 anti‐in‐
flammatory	drug‐activated	gene	(NAG‐1),	has	a	known	role	in	regu‐
lating	tissue	injury	(Zimmers	et	al.,	2005)	and	lipolysis	(Chrysovergis	
et	al.,	2014).	GDF15	is	also	involved	in	mitochondrial	diseases	(Kalko	
et	al.,	2014;	Montero	et	al.,	2016;	Yatsuga	et	al.,	2015)	and	all‐cause	
mortality	(Wiklund	et	al.,	2010),	regulates	appetite,	weight	loss,	and	
cancer‐related	anorexia	(Breit	et	al.,	2011;	Johnen	et	al.,	2007;	Lerner	
et	al.,	2015;	Tsai,	Lin,	Brown,	Salis,	&	Breit,	2016;	Tsai	et	al.,	2013,	
2014;	Villars,	Pietra,	Giuliano,	Lutz,	&	Riediger,	2017).	However,	nei‐
ther	the	functional	role	of	GDFs	(beyond	GDF8)	in	skeletal	muscle,	
nor their regulation, has been described.
In the current study, we investigate whether mTORC1 activity 
is involved in the phenotypic changes associated with muscle aging, 
and	 if	 so,	what	 underlying	mechanisms	 are	 implicated.	We	 report	
here that mTORC1 activity is induced in a subset of aging skeletal 
muscle fibers in both human and mouse, and that these mTORC1‐
activated	 fibers	 often	 exhibit	 degenerative	 changes.	 We	 further	
demonstrate in a transgenic mouse model that activated mTORC1 is 
sufficient to induce oxidative stress in muscle, and myofiber damage 
and loss. Our work establishes that activated mTORC1 transcrip‐
tionally	upregulates	GDFs,	including	GDF3,	5,	and	15,	in	addition	to	
inducing	FoxO	family	members	as	previously	reported,	and	that	the	
GDFs	are	sufficient	to	induce	catabolic	changes	in	skeletal	muscle.	
mTORC1	 activity	 induces	 GDF15	 expression	 via	 upregulating	 the	
phosphorylation	 of	 STAT3.	 Inhibition	 of	 mTORC1	 with	 rapamycin	
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treatment relieves oxidative stress and reduces muscle fiber loss in 
old mice.
2  | RESULTS
2.1 | mTORC1 is activated in aged skeletal muscle 
fibers of both mouse and human, and its overactivity 
co‐localizes with degenerative changes in muscle 
fibers
To explore the functional role of the mTORC1 signaling pathway 
in aged muscle, we first examined mTORC1 activity by probing 
the	 phosphorylation	 of	 its	 downstream	 target	 protein	 S6	 (pS6).	
Immunostaining revealed increased pS6‐stained fibers scat‐
tered within the muscles of aged mice	 (30	month,	 11%	±	2%)	 vs.	
their	young	counterparts	(2	months,	0.3%,	p	<	0.05;	Figure	1a–c).	
The activation of mTORC1 in muscle fibers was also detected at 
12 and 24 months of age, indicating a progressive induction in 
aging	 muscle	 over	 time	 (Supporting	 Information	 Figure	 S1a,b).	
Interestingly, the majority of the pS6‐positive fibers in the aged 
muscle are phenotypically abnormal, demonstrating changes in‐
cluding	 irregular	 shape	 and	 visibly	 smaller	 CSA	 (Figure	 1b	 and	
Supporting	 Information	Figure	S1c).	Among	the	pS6‐positive	fib‐
ers	 at	 30	months	 old,	 76.2%	±	7%	 exhibit	 reduced	 CSA	 and/or	
angular shape, which is significantly higher than the rate in the 
pS6‐negative	fibers	(2.02%	±	1%,	p	<	0.05;	Figure	1d).	In	addition,	
11%	of	 the	pS6+	fibers	show	positive	staining	 for	activated	cas‐
pase	3,	comparing	to	1%	in	pS6‐	fibers	(Figure	1e).
Similarly, mTORC1 activity increases in human skeletal muscle fi‐
bers	during	aging.	In	a	younger	cohort	(42	±	12	years),	human	latissi‐
mus	dorsi	muscle	exhibits	rare	pS6+	fibers	(3%	±	1%).	The	pS6+	fiber	
percentage	 significantly	 increases	 (to	 15%	±	4%,	p	<	0.05)	 in	 older	
latissimus	 (69	±	6	years;	Figure	1f,g),	 consistent	with	 the	 increased	
mTORC1 activity in aged muscle that has been previously reported 
(Markofski	et	al.,	2015).	Approximately	40%	of	the	pS6+	human	mus‐
cle fibers show abnormal phenotypes, including angular shape and 
reduced	 size	 (Figure	 1h).	 Twenty‐two	 percent	 of	 the	 human	 pS6+	
fibers express the apoptotic marker cleaved caspase 3 in the cyto‐
plasm,	compared	to	2%	in	the	pS6−	fibers	(Figure	1i,j).
Taken together, the occurrence of these abnormal degenerative 
phenotypes in skeletal muscle fibers from older mice and humans 
that have increased pS6 staining indicates that elevated mTORC1 ac‐
tivity in aging muscle fibers is associated with muscle fiber damage. 
These degenerative processes, resulted in part from the activation 
of apoptotic signaling, contribute to the age‐related muscle atrophy.
2.2 | Chronic activation of mTORC1 is sufficient to 
cause progressive muscle atrophy, fiber damage, fiber 
death, and muscle weakness
In order to determine whether mTORC1 activation is the cause of 
the degenerative changes in aging skeletal muscle, we first tested 
if mTORC1 activation is sufficient to induce these degenerative 
changes.	We	examined	a	mouse	model	in	which	the	mTORC1	inhibi‐
tor, TSC1, is genetically deleted in a muscle‐specific manner, lead‐
ing to the activation of mTORC1 in skeletal muscle, as described 
previously	(Bentzinger	et	al.,	2013;	Castets	et	al.,	2013;	Tang	et	al.,	
2014).	The	knockout	of	TSC1	 (TSC1	ko)	by	breeding	 floxed	TSC1	
mice	 with	MCK‐cre	 mice	 was	 confirmed	 by	 RT–PCR	 (Supporting	
Information	 Figure	 S2),	 and	 the	 activation	 of	 mTORC1	 was	 vali‐
dated by the positive staining of pS6 in various muscles—gastrocne‐
mius,	TA,	and	soleus	(Figure	2a	and	Supporting	Information	Figure	
S3).	TSC1	ko	mice	displayed	no	discernible	phenotypic	changes	or	
growth	defects	at	2.5	months	of	age,	with	similar	body	size/weight	
and	muscle	weight	as	wt	mice	(Figure	2b–d).	However,	as	they	aged,	
the TSC1 ko mice became physically smaller compared to their wt 
counterparts.	At	18	months	of	age,	the	TSC1	ko	mice	have	a	20%	
lower body weight than wt and exhibit kyphosis often seen with 
severe	illness	and	advanced	age	(Figure	2b,c).	The	weight	of	the	gas‐
trocnemius	and	TA	muscles	were	dramatically	reduced	at	this	age	
to	approximately	60%	of	their	wt	controls	(Figure	2c).	The	relative	
muscle	weight	(muscle	weight	vs.	body	weight)	in	TSC1	ko	mice	was	
also	significantly	reduced	to	~72%	of	the	wt	controls,	indicating	that	
muscle wasting is a primary change following mTORC1 activation 
(Figure	2d).
The histological changes in mTORC1‐activated skeletal muscle 
are also progressive. Cross sections of muscle fibers appear normal 
in	 the	 young	TSC1	 ko	mice	 (1	month),	 but	 the	CSA	of	 the	muscle	
fibers	starts	to	enlarge	at	2.5	months	of	age	(Figures	2e	and	5a).	By	
9 months of age, TSC1 ko muscle fibers have become visibly hetero‐
geneous,	with	17%	±	3%	 shrunken	 fibers	 containing	 central	 nuclei	
interspersed	among	enlarged	 fibers	 (Figure	2e),	whereas	 there	are	
no visible abnormal fibers in the wt muscle at this age. Longitudinal 
sections of 9‐month‐old TSC1 ko muscles reveal that some fibers 
contain long chains of myonuclei aligned head‐to‐tail in the center 
of the muscle fibers; these myonuclear chains are never observed in 
wt	myofibers	(Figure	2f–b)	and	indicate	that	the	affected	fibers	are	
actively regenerating due to damage. In addition, cellular vacuolation 
(Figure	2f–c)	and	death	of	individual	muscle	fibers	(Figure	2f–d)	are	
also seen in the TSC1 ko muscles but not in wt control mice at that 
age	(Figure	2f–a).
We	stained	the	muscle	sections	for	succinate	dehydrogenase	
(SDH)	activity,	which	 identifies	 slow	oxidative	 fibers	 (SDH+)	en‐
riched in mitochondria. Compared to wt mice, TSC1 ko mice ex‐
hibit	a	gradual	loss	of	fast	glycolytic	fibers	(SDH‐)	as	they	age	to	
18	months	(Figure	2g),	 indicating	that	chronic	mTORC1	hyperac‐
tivity	may	lead	to	a	preferential	loss	of	glycolytic	fibers.	Although	
at	2.5	months	of	age	the	muscle	fibers	are	generally	larger	in	TSC1	
ko fibers compared to wt, they become more variable at 18 months 
of age, when most muscle fibers are smaller than wt; though with 
16%	±	3%	of	the	fibers	larger	than	wt	(more	than	twice	the	mean	
size	 of	wt	 fibers;	 Figure	 2h).	 TSC1	 ko	muscle	 is	 thus	 composed	
of widely varied muscle fiber sizes at old age. These phenotypes 
imply that chronic mTORC1 activation leads to the muscle damage 
and atrophy after an initial phase of hypertrophy. Muscle fiber 
number in TSC1 ko mice at 18 months old is significantly reduced. 
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The lateral head of gastrocnemius muscle, for example, loses ap‐
proximately	50%	of	 its	muscle	 fibers	 in	18‐month	TSC1	ko	mice	
(Figure	2i).
The exercise capacity of the TSC1 ko mice is also compromised, 
with significant reduction of their maximum running time on tread‐
mill	at	9	months	of	age	(Supporting	Information	Figure	S4).	We	also	
F I G U R E  1  Activation	of	mTORC1	in	aged	muscle	is	colocalized	with	degenerative	changes	in	both	mouse	and	human	skeletal	muscle.	
(a	and	b)	Immunostaining	on	young	(2.5	months[m])	and	old	(30	m)	mouse	skeletal	muscles	with	antibody	against	pS6	protein,	visualized	
by	DAB	(Diaminobenzidine)	(5x,	40x).	pS6	+	fibers	(brown,	indicated	by	*)	appear	mainly	in	old	muscle,	scattered,	with	angular	shapes	
and	smaller	diameter.	Nuclei	were	stained	with	hematoxylin	(blue).	Scale	bar:	20	µm.	(c)	Increased	pS6	+	fibers	in	old	mouse	TA	muscles.	
~300 fibers/muscle were counted, n	=	3	mice,	*p	<	0.05.	(d)	Quantification	of	the	abnormal	fibers	and	pS6	staining.	In	aged	mice,	the	
percentage	of	abnormal	fibers	is	significantly	higher	among	pS6	+	fibers	than	that	pS6‐	fibers.	~150	fibers/mouse,	n	=	3	mice,	*p	<	0.05.	
(e)	Increased	caspase	3	activity	in	pS6	+	fiber	in	old	muscles.	Consecutive	sections	were	with	anti‐pS6	and	anticleaved	caspase	3	(active	
casp3)	antibodies.	Quantitation	was	performed	on	~100	fibers/mouse,	n	=	3	mice,	*p	<	0.05.	(f)	Immunofluorescence	staining	with	anti‐pS6	
in	young	(23	years,	left	pane)	and	old	(78	years,	middle	pane)	human	latissimus	dorsi	muscles.	pS6	+	fibers	(red)	appear	in	old	muscle,	and	
some	of	these	demonstrate	the	same	angular	shape	and	smaller	diameter	(arrow)	seen	in	pS6	+	fibers	in	old	mouse	muscle.	Cell	membrane	
was	stained	with	wheat	germ	agglutinin	(WGA,	green).	Scale	bar:	50	µm.	Negative	control	(right	panel):	absence	of	primary	antibody.	(g	
and	h)	Quantitative	results	show	the	higher	percentage	of	pS6	+	fibers	in	old	muscle	(g)	and	the	higher	percentage	of	fibers	with	abnormal	
phenotypes	(h)	(smaller	size	and/or	irregular	shape)	in	pS6+	vs.	pS6−	fibers.	200	fibers/muscle,	young:	n = 6 muscles; old: n = 7 muscles; 
*p	<	0.05.	(i)	pS6+	muscle	fibers	stain	positively	for	activated	(cleaved)	caspase	3.	Consecutive	muscle	sections	were	stained	with	antibodies	
against	pS6	and	cleaved	caspase	3	(act.	Casp3),	respectively.	Cell	membrane	was	stained	with	WGA.	Matching	fibers	are	indicated	with	
arrows.	Scale	bar	25	µm.	(j)	Quantitative	result	shows	a	higher	percentage	of	positive	staining	for	activated	caspase	in	pS6+	than	pS6−	
muscle	fibers	in	old	muscles.	~200	fibers/muscle,	counted	in	7	muscles,	*p	<	0.05
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F I G U R E  2   Muscle‐specific activation of mTORC1 in mice leads to progressive muscle fiber damage, fiber death, and loss of muscle mass. 
(a)	Immunofluorescence	staining	with	anti‐pS6	antibody	in	muscle	harvested	from	TSC	ko	and	wt	mice	at	2.5‐month‐old.	pS6+	staining	
indicates	that	the	mTORC1	signaling	pathway	is	activated	in	both	slow	(Sol:	soleus	muscle)	and	fast‐twitch	muscles	(TA:	tibialis	anterior;	
Gastroc:	gastrocnemius	muscle)	of	TSC1	ko	animals.	(b	and	c)	Age‐dependent	reduction	in	body	size	and	weight	in	TSC1	ko	mice.	The	
body	weight	of	TSC1	ko	mice	is	reduced	at	18	months	(18	m)	relative	to	wt	controls.	n	=	4,	*p	<	0.05.	Note	that	the	old	(18	m)	TSC1	ko	mice	
develop	a	hunched	back.	(d)	Age‐dependent	reduction	in	muscle	mass	in	TA	and	gastrocnemius	muscles	of	TSC	ko	mice	vs.	wt	controls.	
n	=	4,	**p	<	0.001	at	18	months.	Note,	the	muscle/body	weight	ratio	is	also	significantly	reduced	in	TSC	ko	mice.	(e)	Histology	of	mTORC1‐
activated	muscles	and	their	wt	controls.	Cross	sections	of	TA	muscle	at	1	m,	2.5	m,	and	9	m	(HE	staining).	Note	that	some	fibers	in	TSC1	
ko	muscle	at	9	m	are	shrunken	(arrows	and	asterisks)	and/or	have	centrally	located	nuclei	(arrows).	(f)	Longitudinal	sections	of	TA	muscle	at	
2.5	m	and	9	m	(HE	staining).	Note	that	in	9	m	TSC1	ko	muscle,	some	fibers	contain	nuclear	chains	(arrow,	b),	cytoplasmic	vacuolation	(arrow,	
c),	and	death	(arrow,	d).	(g)	Preferential	loss	of	glycolytic	muscle	fibers	in	response	to	mTORC1	activation.	SDH	enzymatic	activity	was	
assayed	on	sections	from	the	lateral	head	of	the	gastrocnemius	muscle.	Note	that	predominantly	glycolytic	(SDH‐)	fibers	are	lost	in	TSC1	
ko	muscle	at	18	m.	(h)	Distribution	of	the	cross‐sectional	area	(CSA)	of	the	muscle	fibers	from	wt	and	TSC1	ko	mice	at	18	months.	Note,	
the	leftward	shift	of	the	distribution	curve	in	the	ko	indicating	decreased	CSA.	(i)	Reduced	fiber	number	in	TSC1	ko	muscle	at	18	m.	Cross	
sections	of	the	lateral	head	of	gastrocnemius	muscle	were	taken,	and	fiber	numbers	in	a	10x	image	from	an	identical	location	(~1/4	of	the	
lateral	head)	were	counted,	n	=	4	mice,	*p	<	0.01.	(j)	Reduced	lifespan	in	the	TSC1	ko	mice,	compared	to	wt	controls.	The	comparison	of	the	
survival	rate	between	wt	and	ko	mice	was	examined	by	the	log‐rank	test	(implemented	in	STATA).	The	log‐rank	p value is p < 0.0001. The 
median	lifespan	of	the	TSC1	ko	mice	was	18	months.	Detail	in	supporting	information	Figure	S4e
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observed that both the maximal and specific isometric contractile 
forces	of	isolated	TSC1	ko	muscles	(both	EDL	and	Soleus)	are	reduced	
compared	 to	 wt	 controls	 (Supporting	 Information	 Figure	 S4	 and	
Table	S1).	In	addition,	the	lifespan	of	the	TSC1	ko	mice	is	significantly	
shorter	(p	<	0.0001),	with	only	about	39%	of	TSC1	ko	mice	surviving	
to	18	months	(Figure	2j	and	Supporting	Information	Figure	S4).	This	
may be due to whole‐body metabolic changes driven by mTORC1 
activation	(Guridi	et	al.,	2015),	respiratory	failure	secondary	to	com‐
promised respiratory muscles, or other incompletely evaluated phe‐
notypes	of	accelerated	aging	associated	with	mTORC1	and/or	GDF15.
2.3 | Chronic activation of mTORC1 induces 
abnormal mitochondria in skeletal muscle, 
accompanied by oxidative stress and the activation of 
caspase 3
We	also	examined	the	ultrastructure	of	the	muscles	by	transmission	
electron	microscopy	 (TEM)	with	 particular	 attention	 to	mitochon‐
drial	changes.	In	TSC1	ko	muscle	(~7	months	old),	sarcomere	length,	
structure, and organization, as well as the alignment of sarcomeres 
and myofilaments, appear similar to wt at this age. Mitochondria, 
however, are significantly enlarged vs. wt, and they are no longer 
restricted	 to	 the	 small	 area	 flanking	 the	Z	band,	where	mitochon‐
dria are normally located. Rather, the mitochondria became gigantic, 
often spanning the full length of the sarcomere. Similarly, muscle 
fiber cross sections reveal the density of TSC1 ko myofilaments to 
be normal, but the mitochondria are round, with reduced internal 
cristae	density,	indicating	mitochondrial	matrix	swelling	(Figure	3a).
The mitochondrial content is significantly increased in TSC1 ko 
muscle,	based	upon	 the	 ratio	of	mitochondrial	 genes	 (COXII/cyto‐
chrome	C	oxidase	II	and	Cytob/Cytochrome	b),	relative	to	the	myo‐
nuclear	gene	beta‐actin	 (Figure	3b).	This	 increase	 in	mitochondrial	
content may result from both accelerated mitochondrial biogenesis 
and inhibition of autophagy, driven by the hyperactive mTORC1 
in	TSC1	ko	muscle.	However,	 these	enlarged	and	proliferating	mi‐
tochondria	appear	 to	be	dysfunctional,	 since	 the	 relative	RNA	ex‐
pression levels of genes reflective of mitochondrial function such as 
COX5a	and	cytochrome	b,	relative	to	mitochondrial	DNA/content,	
are	significantly	reduced	(Figure	3c).
We	 suspected	 that	 the	presence	of	 abnormal	 and	 functionally	
compromised mitochondria in TSC1 ko muscles would lead to mi‐
tochondrial	oxidative	stress	(MOS).	Indeed,	reactive	oxygen	species	
(ROS)	are	increasingly	accumulated	in	TSC1	ko	muscle	with	age,	as	
demonstrated	by	dihydroethidium	(DHE)	staining	(Figure	3d).	Further,	
immunoreactivity for the apoptotic marker cleaved caspase‐3 is in‐
duced in mTORC1‐activated muscle fibers, accompanied by centrally 
located	myonuclei	 (Figure	3e).	Together,	 these	data	strongly	 imply	
that MOS‐associated intrinsic apoptosis is induced by chronic acti‐
vation of mTORC1.
2.4 | Activation of mTORC1 induces the 
expression of growth differentiation factors and 
genes/proteins involved in mitochondrial oxidative 
stress and apoptosis
To begin to understand the molecular mechanisms underlying the 
phenotypic changes seen in the skeletal muscle of the mTORC1‐hy‐
peractive	 TSC	 ko	 mice,	 we	 performed	 mRNA	 microarray.	 Muscle	
samples	(gastrocnemius)	from	2.5‐	and	18‐month‐old	wt	and	TSC1	
ko	mice	were	harvested	and	subjected	to	Agilent	single	color	mRNA	
microarray.	Data	were	 analyzed	 by	GeneSpring	 and	DAVID	 bioin‐
formatics	analysis	software	(Figure	4a).	As	summarized	in	Figure	4b,	
genes associated with mitochondria, stress response, and protein 
degradation	 pathways	 (e.g.,	 lysosomal	 and	 ubiquitin–proteasome	
systems)	 are	 significantly	upregulated	 in	TSC1	ko	muscles	 at	 both	
2.5	and	18	months	old.	The	genes	involved	in	mitochondrial	oxida‐
tive stress and programmed cell death are also dramatically induced, 
but primarily only at 18 months. This reveals a progressive induction 
of oxidative stress and apoptosis in skeletal muscle following chronic 
mTORC1 activation. The reduced expression of mitochondrial func‐
tion‐associated	gene	(Mss51),	antioxidant	gene	(Thioredoxin	2),	and	
anti‐apoptotic	genes	(Bcl2),	and	the	increased	expression	of	pro‐ap‐
optotic	genes	(Bim,	Bax)	were	further	validated	by	quantitative	PCR	
(Figure	4c).
Considering	all	of	the	genes	with	upregulated	expression,	GDF15	
is among the most strongly induced, and it is persistently increased 
from	 2.5	 to	 18	months.	 Other	 members	 of	 the	 GDF	 family,	 such	
as	GDF3	and	5,	 are	 also	 induced,	 but	GDF8/myostatin	 is	 reduced	
F I G U R E  3  Activated	mTORC1	leads	to	abnormal	mitochondrial	proliferation,	oxidative	stress,	and	muscle	fiber	apoptosis.(a)	Electron	
microscopic view of muscle tissue to demonstrate sarcomeres and mitochondria. Left panel: The structure and alignment of the sarcomeres 
are	normal	in	7	m	TSC1	ko	muscles	(scale	bar	is	1	µm).	Middle	panel:	The	TSC1	ko	muscle	has	normal	myofilaments,	but	mitochondria	are	
increased	to	sometimes	enormous	size	(arrows).	Normal	mitochondria	in	wt	muscle	are	indicated	with	asterisks	(*).	Scale	bar:	200	nm.	
Right	panel:	cross‐sectional	view	of	sarcomere.	Normal	density	and	distribution	of	myofilaments,	but	mitochondria	(arrows)	in	TSC1	ko	
muscle	become	round	and	lose	internal	cristae	density	vs.	wt	mitochondria	(*).	(b)	Mitochondrial	content	shown	by	relative	DNA	ratio	of	
mitochondrial	vs.	myonuclear	genes.	Cytb,	cytochrome	b;	COXII,	cytochrome	C	oxidase	subunit	II.	n	=	4,	*p	<	0.05.	(c)	The	reduction	in	the	
relative	levels	of	the	mRNAs	of	mitochondrial	function‐associated	genes	vs.	mitochondrial	content	(DNA)	in	TSC1	ko	muscle.	The	mRNA	
expression	of	the	mitochondrial	function‐associated	genes	(Cytb	and	Cox5a)	was	quantified	and	normalized	to	the	mitochondrial	DNA	levels	
represented	here	by	Cytb	DNA	and	COXII	DNA,	respectively.	mRNA	and	DNA	levels	are	both	quantified	by	real‐time	PCR.	n	=	4,	*asterisk	
denotes p	<	0.05	for	the	comparison	of	mRNA/mt	DNA	ratios	between	the	ko	and	the	Wt	control,	which	is	set	as	1	(unity).	(d)	Increased	
oxidative	stress	in	18	m	TSC1	ko	muscle.	DHE	staining	(red)	was	performed	on	muscle	cryosections.	Note	that	reactive	oxygen	species	(ROS)	
is	detected	at	a	higher	level	in	TSC1	ko	muscle	at	18	m,	shown	by	intensity	quantitation	in	the	below	bar	graph.	n	=	3,	*p	<	0.05.	(e)	Induced	
apoptosis	in	TSC1	ko	muscle.	Immunostaining	with	anticleaved	caspase‐3,	counterstained	with	DAPI	on	9	m	muscle.	Note,	caspase‐3+ fibers 
(red)	are	present	in	TSC1	ko	muscle,	and	have	central	nuclei	(inset)
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(Figure	 4d),	 and	 the	 remaining	 GDFs	 are	 not	 significant	 changed.	
These	gene	expression	levels	were	also	further	validated	by	quanti‐
tative	PCR	(Figure	4e).	The	increased	expression	of	GDF15	was	also	
further	 confirmed	 at	 the	 protein	 level	 (Figure	 4f).	 In	 addition,	 the	
expression of component proteins in the mitochondrial respiratory 
chain—such	 as	 the	 complex	V	 component	ATP5A,	 the	 complex	 III	
component	UQCRC2,	the	complex	IV	component	MTCO1,	the	com‐
plex	II	component	SDHB,	and	the	complex	I	component	NDUFB8—is	
upregulated, suggesting that mTORC1 increases mitochondrial 
content. The oxidative stress marker—protein carbonylation, re‐
vealed	by	DNP	 (dinitrophenyl)	 levels—is	also	 increased	 (Figure	4f).	
A	 measured	 increase	 in	 polyubiquitinated	 proteins	 is	 also	 consis‐
tent with the transcriptomic profiling that shows the induction of 
genes	involved	in	ubiquitin–proteasome‐mediated	protein	degrada‐
tion. Taken together, these molecular changes reveal that mTORC1 
activation leads to MOS, protein degradation, and apoptosis—and 
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F I G U R E  4  Activated	mTORC1	alters	the	transcriptomic	expression	profile	of	genes	involved	in	mitochondrial	oxidative	stress	and	
apoptosis,	as	well	as	members	of	the	GDF	family.	(a)	Heatmap	of	the	clustered	transcriptomic	profiles	(p	<	0.05)	comparing	wt	and	TSC1	
ko	muscles	at	2.5	m	and	18	m,	analyzed	by	GeneSpring	software.	(b)	Signaling	mined	by	DAVID	bioinformatics	software.	The	number	of	
significantly	altered	genes	(p	<	0.05)	in	each	pathway/event	is	listed.	(c)	Quantitative	PCR	to	validate	the	altered	expression	of	genes	related	
to	mitochondria	and	oxidative	stress.	Gamma	actin	was	used	as	normalization	control	(F.C,	Fold	change).	Antioxidant	and	anti‐apoptotic	
genes	(e.g.,	Mss51,	trx2,	and	Bcl2)	are	decreased,	whereas	the	apoptotic	genes	(e.g.,	Bim	and	Bax)	are	increased.	n	=	3,	*p	<	0.05	compared	
to	wt	controls.	(d)	The	expression	profile	of	GDF	family	members	comparing	wt	and	TSC	ko	at	2.5	and	18	months.	GDF	15	is	by	far	the	
most	dramatically	upregulated.	ns:	no	significant	change.	(e)	Quantitative	PCR	validating	the	altered	expression	of	genes	in	the	GDF	family.	
Gamma	actin	was	used	as	normalization	control	(F.C,	Fold	change).	n	=	3,	*p	<	0.05	compared	to	wt	controls.	(f)	Protein	expression	profiles	
by	Western	blot	show	the	induction	of	GDF15,	mitochondrial	components,	protein	oxidation,	and	polyubiquitination	(ubi)	in	mTORC1‐
activated	muscle	(18	m),	actin	as	loading	control.	GDF15	blot:	black	arrow	pointing	to	mature	dimer	of	GDF15	(~25	kDa);	asterisk	pointing	to	
immature	intermediate	GDF15	protein	products.	The	presence	of	multiple	bands	of	GDF15	is	further	explained	and	validated	in	Supporting	
Information	Figures	S5,	S6
(b)(a)
–15.4 0 +15.4
intensity
18 m ko 10 w ko 10 w wt 18 m wt
10 w 18 m 
Up Down Up DownCategory
Mitochondrion 
(GOTERM_CC_FAT) 342 5 299 67
Programmed cell death 
(GOTERM_BP_FAT) 5 (anti-) 0 151 0
Response to stress 
(GOTERM_BP_FAT) 120 0 116 0
Oxidative stress 
(GOTERM_BP_FAT)
0 0 25 0
Lysosome 
(SP_PIR_KEYWORDS)
47 0 48 0
Ubl conjugation pathway 
(SP_PIR_KEYWORDS)
170 0 147 0
(P<0.05, DAVID bioinformatics)
(c)
12
wt TSC1 ko
GDF15
Mito-
profile
DNP
Actin
(e)
10 w ko/wt
18 m ko/wt
F.
 C
. o
f m
R
N
A 
( b
y 
qP
C
R
)
GDF3 GDF5 GDF8 GDF15
wt0
5
10
15
20
25
30
35
40
45
0
0.5
1
1.5
2
2.5 10 w ko/wt 18 m ko/wt
wt
Mss51 Trx2 Bcl2 Bim Bax
F.
 C
. o
f m
R
N
A
(f)
* *
* *
*
*
*
*
*
*
* **
(d)
Ubi
(b
y
qP
C
R
)
CV
CIII
CIV
CII
CI
okw0 1 okm8110 w wt 18 m wt
GDF1
GDF2
GDF3
GDF5
GDF6
GDF7
GDF8
GDF9
GDF10
GDF11
GDF15
F. C. (ko/wt)
10 w 18 m
–1.5 
ns
1.1
2.3
ns
ns
–1.7
ns
ns
ns
17 74
–2.5 
ns
3.2
2.1
ns
ns
–4.1
ns
ns
ns
     |  9 of 20TANG eT Al.
the	GDF	family	appears	to	be	a	likely	participant	in	the	regulation	of	
these processes.
2.5 | Inhibition of mTORC1 activity with rapamycin 
in TSC1 ko mice normalizes the molecular and 
phenotypic changes in skeletal muscles
To further investigate if the associated changes in TSC1 ko mice are 
due to mTORC1 hyperactivity, we treated TSC1 ko mice with rapa‐
mycin	for	8	weeks	beginning	at	5	weeks	of	age.	The	main	phenotypic	
change in the skeletal muscle of TSC1 ko mice at 13 weeks is en‐
larged	fiber	CSA	(Figure	5a).	We	observed	that	inhibition	of	mTORC1	
activity	 with	 rapamycin	 restores	 fiber	 CSA,	 which	 is	 increased	 in	
TSC1	ko	muscle,	back	to	that	of	wt	(Figure	5a).
At	the	molecular	 level,	 rapamycin	treatment	normalized	the	al‐
tered mTORC1 signaling pathway by reducing the phosphorylation 
levels of S6K1 and S6 without affecting the protein levels of S6K1, 
S6,	and	GSK3.	Inhibition	of	mTORC1	also	led	to	the	suppression	of	
the	elevated	expression	of	GDF15	protein	(Figure	5b).	Interestingly,	
a	 downstream	 signaling	mediator	 of	 the	 GDF	 family,	 Smad3,	 was	
significantly	activated	(phosphorylated)	in	TSC1	ko	muscle,	but	this	
returned	to	baseline	with	inhibition	of	mTORC1	activity	(Figure	5b).	
However,	Smad2	phosphorylation	was	not	significantly	affected	by	
mTORC1 activity and remained unchanged with rapamycin treat‐
ment.	On	 the	other	 hand,	 the	 suppressed	Akt	 activity	 (pAkt/total	
Akt)	 in	 the	 TSC1	 ko	 was	 recovered	 by	 rapamycin	 treatment,	 and	
the	 activation	 of	 FoxO,	 revealed	 by	 the	 level	 of	 phosphorylated	
FoxO1/total	FoxO1,	returned	to	baseline	with	rapamycin	treatment	
(Figure	 5b).	 The	 upregulated	 transcriptional	 expression	 of	 GDF15	
and	FoxO3	mRNAs	was	 also	 completely	 normalized	 by	 rapamycin	
treatment	(Figure	5c).
Thus, both the molecular and the phenotypic changes within 
skeletal muscle which are present in TSC1 ko mice are prevented by 
rapamycin treatment, indicating that the changes observed in TSC1 
ko mice are due to the activation of mTORC1.
2.6 | GDFs are sufficient to induce oxidative 
stress and catabolic activity in skeletal muscle
After	the	identification	of	GDFs	as	downstream	targets	of	mTORC1	
activation, we examined if they might subserve the mTORC1‐induced 
oxidative	stress	and	apoptosis	in	skeletal	muscle.	Since	GDF15	is	the	
most	robustly	induced	gene	in	the	GDF	family	in	mTORC1‐activated	
muscle,	we	used	GDF15	to	perform	the	further	tests.	We	transfected	
F I G U R E  5   Inhibition of mTORC1 
activity with rapamycin prevents the 
altered phenotype and molecular signaling 
in	TSC1	ko	muscle.	(a)	Distribution	
of	fiber	CSA	in	wt,	TSC1	ko,	and	TSC	
ko	+	rapamycin.	Muscle	fiber	enlargement	
seen	in	mTORC1	activated	muscle	(~3	m)	
is inhibited by 8 weeks of rapamycin 
treatment,	beginning	at	5	weeks	old.	
(b)	Molecular	signaling	that	is	altered	in	
the ko mouse muscle is normalized with 
rapamycin to a wt‐like expression pattern. 
Western	blot	showing	altered	activities	
in	the	mTORC1‐S6K‐S6,	GDF‐Smad,	
and	Akt‐FoxO	signaling	pathways.	Note	
that pS6K1 and pS6 levels, as well as 
GDF15	and	pSmad3,	are	all	dramatically	
increased in TSC1 ko mice, but rapamycin 
treatment recovers these changes. 
In	contrast,	decreased	pAkt/Akt	and	
pFoxO1/FoxO1	in	TSC1	ko	muscle	is	
upregulated by rapamycin treatment. 
(c)	The	transcriptional	upregulation	of	
FoxO3	and	GDF15	by	activated	mTORC1	
is	suppressed	by	rapamycin.	mRNA	levels	
were	measured	by	quantitative	PCR,	and	
the level of gamma actin was used control. 
Fold	changes	vs.	wt	were	shown.	n = 3, 
*p	<	0.05
(a)
(c)
(b)
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C2C12	 cells	 with	 control	 GFP	 and	 GDF15‐GFP	 plasmids,	 respec‐
tively.	One	day	later,	the	GFP+	cells	were	sorted	by	FACS	and	then	
stained	with	Annexin	V	 (AV)	 and	Propidium	 Iodide	 (PI)	 to	 identify	
apoptosis.	After	GDF15	 transfection,	 each	of	 the	 apoptotic	mark‐
ers	AV	and	PI	are	significantly	induced	(Figure	6a,b).	In	culture,	the	
GDF15‐transfected	cells	are	consistently	positive	for	cleaved	(active	
form)	caspase	3,	shown	by	immunostaining	(Figure	6c).	Recombinant	
GDF15	(10	ng/ml,	for	4	days)	also	induces	the	levels	of	cleaved	cas‐
pase	 3	 in	 cultured	 myotubes,	 as	 shown	 by	Western	 blot	 analysis	
(Figure	6d).	Similarly,	 treatment	of	GDF3	and	GDF5	 (10	ng/ml,	 for	
4	days)	also	leads	to	the	activation	of	caspase	3	activity	(Figure	6d).	
We	further	confirmed	the	apoptotic	effect	induced	by	GDFs	in	vivo	
by	 electroporation	 of	 GDF15	 plasmid	 (GDF15‐GFP)	 and	 control	
(GFP)	 into	TA	muscle.	Fourteen	days	after	GDF15	electroporation,	
~9%	of	the	GDF15‐transfected	muscle	fibers	show	positive	staining	
for	 cleaved	caspase	3	 (Figure	6e,f),	 but	none	of	 the	 control	 fibers	
show positive staining of caspase 3.
We	 next	 tested	 if	 GDF15	 participates	 in	 the	 induction	 of	
mTORC1‐induced	apoptosis.	GDF15	siRNA	was	transfected	into	an	
mTORC1‐activated	C2C12	 stable	 cell	 line	 harboring	 TSC1	 shRNA.	
Three	 days	 later,	 the	 cells	 were	 stained	 with	 Annexin	 V	 and	 PI.	
Successful	 knockdown	 of	 GDF15	 expression	 was	 confirmed	 by	
quantitative	PCR	(Supporting	Information	Figure	S5).	As	in	the	case	
of in vivo mTORC1 activation in skeletal muscle, mTORC1 activation 
following TSC1 silencing in cultured cells also increases the levels 
of	 both	 apoptotic	 markers.	 Silencing	 GDF15	 with	 GDF15	 siRNA	
significantly reduces the levels of these markers, indicating the 
GDF15	likely	plays	a	role	in	the	development	of	apoptosis	induced	
by	mTORC1	(Figure	6g).	In	addition	to	the	activation	of	caspase‐me‐
diated	apoptotic	 changes,	GDF15	also	upregulates	 the	 autophagic	
marker	LC3	(Figure	6h)	and	induces	protein	ubiquitination	and	oxi‐
dation,	as	demonstrated	by	the	upregulation	of	dinitrophenyl	(DNP)	
and	 protein	 polyubiquitination	 (ubi;	 Figure	 6i).	 This	 suggests	 that	
GDF15	mediates	mTORC1‐induced	degenerative	effects	by	activat‐
ing several catabolic pathways.
We	 also	 investigated	 the	 downstream	 signaling	 regulated	 by	
GDF15	 by	 analyzing	 recombinant	 GDF15‐treated	 myotubes.	 This	
allowed	us	to	identify	Smad3	and	FoxO1	as	downstream	targets	of	
GDF15.	We	 found	 that	 GDF15	 treatment	 induces	 the	 phosphor‐
ylation	 of	 Smad3,	 but	 not	 Smad2,	 and	 dephosphorylates	 FoxO1	
(Figure	 6i),	 leading	 to	 their	 activation.	 GDF‐dependent	 regulation	
of	Smad3	and	FoxO1	was	 further	confirmed	by	overexpression	of	
GDF15	 through	 transfecting	 a	 GDF15‐expressing	 plasmid	 in	 cul‐
tured	cells	(Supporting	Information	Figure	S7).	Consistently,	GDF15	
upregulates	 the	 reporter	 activities	 of	 both	 FoxO1	 and	 Smad3,	 as	
demonstrated	 by	 cotransfection	 of	 a	 GDF15‐expressing	 plasmid	
with	 the	FoxO1	reporter	gene	6DBE,	or	 the	Smad3	reporter	gene	
3TP‐Lux,	respectively	(Figure	6j).	Interestingly,	the	phosphorylation	
levels	of	Akt	protein	appear	not	to	be	affected	by	GDF15	(Figure	6i),	
indicating	that	GDF15	only	mediates	part	of	mTORC1’s	effect,	with	
the	reduction	of	Akt	phosphorylation/activity	in	mTORC1‐activated	
muscle driven by other mechanisms, for example, the S6 kinase/
Grb10‐IRS	feedback	route	(Saxton	&	Sabatini,	2017).
2.7 | mTORC1 upregulates the expression of GDF15 
by phosphorylating STAT3
To determine the mechanism by which mTORC1 increases the ex‐
pression	of	GDF15,	we	performed	bioinformatic	analysis	of	GDF15’s	
promoter	 sequence.	 We	 found	 several	 consensus	 DNA	 elements	
that	the	transcription	factor	STAT3	may	bind	within	the	promoter.	
It	 is	 known	 that	 STAT3	 is	 regulated	 by	 mTORC1’s	 kinase	 activity	
through	directly	 phosphorylating	 the	STAT3	protein	 at	 serine	727	
(S727),	and	this	phosphorylation	increases	STAT3’s	activity	(Laplante	
&	Sabatini,	2013;	Wen,	Zhong,	&	Darnell,	1995;	Yokogami,	Wakisaka,	
Avruch,	&	Reeves,	2000).	Therefore,	we	 speculated	 that	mTORC1	
transcriptionally	upregulates	GDF15	by	activating	the	transcription	
factor	STAT3.
We	 first	 examined	 if	 STAT3‐S727	 is	 phosphorylated	 at	 S727	
upon the activation of mTORC1 in skeletal muscle. Shown in 
Figure	7a	with	a	 specific	 antibody	against	S727	of	STAT3	protein,	
the	phosphorylation	level	of	STAT3	at	serine	727	is	indeed	elevated,	
and rapamycin treatment reduces the level of phosphorylation. 
This	mTORC1‐dependent	regulation	of	STAT3	is	mainly	at	the	post‐
translational	 level,	 since	mRNA	 levels	of	STAT3	remain	unchanged	
(Figure	 7b).	 Consistently,	 the	 aged	 muscle	 fibers	 with	 activated	
mTORC1	also	show	the	positive	staining	of	pSTAT3‐S727	(Figure	7c).	
We	also	confirmed	that	 in	cultured	C2C12	myotubes,	 inhibition	of	
mTORC1	 activity	 with	 rapamycin	 suppresses	 STAT3‐S727’s	 phos‐
phorylation	 and	 GDF15	 expression	 (Figure	 7d).	 Increasing	 STAT3	
activity	by	overexpression	of	a	constitutively	active	STAT3	(STAT3c)	
is	able	to	induce	GDF15	expression	in	both	cultured	cells	(Figure	7e)	
and	mouse	skeletal	muscle	(Figure	7f).	On	the	other	hand,	inhibition	
of	STAT3	activity	with	a	small‐molecule	inhibitor,	Stattic,	suppresses	
GDF15	 expression	 (Figure	 7g	 and	 Supporting	 Information	 Figure	
S8).	Decreasing	STAT3	expression	with	STAT3	siRNA	also	 reduces	
GDF15	level	(Figure	7h).
To	 further	 examine	 whether	 STAT3	 transcriptionally	 upreg‐
ulates	 GDF15	 via	 directly	 binding	 to	 the	 GDF15	 promoter	 se‐
quence,	 we	 performed	 chromatin	 immunoprecipitation	 (CHIP)	
assay.	A	 consensus	DNA	element	 that	 can	bind	with	 STAT3,	 ag‐
cctttcacagaaagag,	 is	 located	 at	 −551	 to	 −568,	 upstream	 of	 the	
transcription	 initiation	 site	 of	 GDF15.	 We	 demonstrated	 that	
overexpression	of	STAT3	 increases	STAT3’s	binding	 to	 this	DNA	
sequence,	whereas	rapamycin	treatment	reduces	STAT3’s	binding	
to	 the	 consensus	 sequence	 in	 the	 GDF15	 promoter	 in	 cultured	
myotubes	(Figure	7i–k).
2.8 | Inhibition of mTORC1 with rapamycin blocks 
GDF expression and oxidative stress in elderly 
mice and prevents age‐related muscle fiber loss
Finally,	we	examined	if	inhibiting	mTORC1	activation	in	aged	skeletal	
muscle could prevent age‐related deleterious changes in the mus‐
cle.	For	this	experiment,	mice	were	treated	with	rapamycin	(14	ppm)	
from	~270	days	to	~900–1,099	days	of	age,	as	described	(Harrison	
et	al.,	2009;	Miller	et	al.,	2014).	Age‐dependent	induction	of	GDFs	
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F I G U R E  6  GDF	is	sufficient	to	induce	apoptosis	in	muscle	cells	and	is	required	for	mTORC1‐induced	apoptosis	through	regulation	of	
Smad3,	FoxO1,	and	oxidative	stress	(a)	GDF15	induces	apoptotic	changes	in	cultured	cells.	C2C12	cells	were	transfected	with	GDF15‐GFP	
and	control	GFP	plasmids.	One	day	later,	cells	were	harvested,	stained	with	Annexin	V	and	Propidium	Iodide	(PI),	and	analyzed	by	flow	
cytometry.	Shown	is	the	distribution	of	GFP+	and	GDF15‐GFP+	cells.	(b)	Quantitative	data	of	the	distribution	of	the	positively	stained	
cells	in	the	different	quadrants.	n	=	3,	*p	<	0.05.	(c)	GDF15‐transfected	cells	show	positive	staining	of	cleaved	caspase	3.	Immunostaining	
was	performed	with	anticleaved	caspase	3	(red),	3	days	after	transfection	of	GDF15‐GFP	(green)	into	C2C12	cells.	(d)	GDF	increases	the	
protein	level	of	activated/cleaved	caspase	3.	Recombinant	GDF3,	5,	and	15	(10	ng/ml)	was	used	to	treat	differentiated	C2C12	myotubes	
for	4	days,	followed	by	detection	of	cleaved	caspase	3	by	Western	blot	analysis.	(e	and	f)	GDF15	activates	caspase	3	in	vivo.	TA	muscle	
was	electroporated	with	GDF15‐GFP	or	control	GFP	plasmids	(20	μg/injection).	Fourteen	days	later,	TA	muscles	were	harvested	and	fixed	
with	paraformaldehyde	for	whole‐mount	staining	(e)	or	cross‐sectional	staining	(f)	with	anticleaved	caspase	3.	Note	that	some	GDF15+	
fibers	stain	positively	for	cleaved/activated	caspase	3	(red).	(g)	GDF15	is	required	for	the	development	of	apoptosis	induced	by	activated	
mTORC1.	A	stable	C2C12	cell	line	that	overexpresses	TSC1	shRNA	was	transfected	with	control	and	GDF15	siRNAs	(each	at	20	nM,	Santa	
Cruz	Biotechnology)	to	silence	GDF15.	Flow	cytometry	was	performed	4	days	after	transfection.	Activation	of	mTORC1	induces	apoptotic	
markers	(top	panel),	but	the	induced	apoptosis	was	significantly	suppressed	by	transfected	GDF15	siRNA	(lower	panel).	n	=	3,	*p	<	0.05.	(h)	
GDF15	increases	the	levels	of	autophagic	marker,	LC3,	revealed	by	Western	blot	analysis.	Increased	protein	levels	of	both	LC3‐I	and	LC3‐II,	
3	days	after	transfection	of	GDF15	into	C2C12	cells.	(i)	GDF15	induces	protein	oxidation	(DNP),	polyubiquitination	(Ubi),	and	activation	
of	Smad3	and	FoxO1.	C2C12	myotubes	were	treated	with	recombinant	GDF15	protein	at	1	and	10	ng/ml	for	48	hr.	Western	blot	analysis	
is	shown.	Note	that	GDF15	phosphorylates	Smad3	and	dephosphorylates	FoxO1.	(j)	GDF15	increases	the	activity	of	FoxO's	and	Smad's	
reporter	gene.	GDF15‐expressing	plasmid	was	cotransfected	into	C2C12	cells,	together	with	a	FoxO1	reporter	gene	6DBE,	or	a	Smad3	
reporter	gene	3TP‐Lux,	as	well	as	a	nonreporter	control	pCS2‐beta‐Gal,	respectively.	Luciferase	(reporter)	and	beta‐Gal	(nonreporter	
control)	activities	were	measured	3	days	later,	and	luciferase	activity	was	normalized	to	beta‐Gal	activity
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and	phosphorylated	STAT3	(S727)	was	observed	in	both	human	and	
mouse	muscle	(Supporting	Information	Figure	S9).	Rapamycin	treat‐
ment in this setting efficiently inhibits the phosphorylation of S6 
and	 STAT3	protein,	 and	 simultaneously	 reduces	 the	 expression	of	
GDF15,	protein	oxidation	(carbonylation,	DNP),	and	cleaved	caspase	
3	(Figure	8a).	A	similar	result	is	observed	at	the	transcriptional	levels	
for	GDF3,	GDF5,	and	GDF15	(Figure	8b).	We	also	evaluated	the	level	
of intracellular oxidative stress by measuring oxidized proteins and 
found that age‐induced oxidative stress is suppressed by rapamycin 
treatment	 (Figure	8c).	The	centrally	 located	nuclei	 that	are	associ‐
ated with muscle damage and regeneration and are induced in aged 
muscle are significantly fewer in rapamycin‐treated than control, 
aged	animals	(Figure	8d).	Age‐dependent	reduction	in	muscle	fiber	
number is also recovered by rapamycin treatment. The fiber number 
in the rapamycin‐treated muscle is significantly higher than in the 
age‐matched	control	group	(Figure	8e).
3  | DISCUSSION
Understanding the regulatory mechanisms underlying muscle aging 
is critical to the development of therapeutic interventions against 
sarcopenia.	We	report	here	 that	mTORC1	signaling	 is	dramatically	
activated in a subset of aging muscle fibers and that these same fib‐
ers show degenerative changes. Inhibition of mTORC1 activity re‐
duces oxidative stress and muscle fiber damage, and it prevents fiber 
damage and loss in aged muscle. Therefore, the level of mTORC1 ac‐
tivity in muscle fibers is closely associated with phenotypic changes 
that occur in naturally aging muscle.
To understand how activated mTORC1 leads to muscle damage 
and	loss,	we	examined	a	TSC1‐null	mouse	model	(Bentzinger	et	al.,	
2013;	Castets	et	al.,	2013;	Tang	et	al.,	2014).	We	show	that	chronic	
activation of mTORC1 induces a degenerative muscle phenotype 
consisting of abnormal and dysfunctional mitochondria, oxidative 
stress, apoptosis, and fiber death. These mTORC1‐driven changes 
are remarkably similar to those observed in normal, aged muscle 
(Arking,	 2006;	 Demontis	 et	 al.,	 2013;	 Hepple,	 Ross,	 &	 Rempfer,	
2004; Larsson et al., 1978; Marzetti et al., 2009; Miller et al., 2008; 
Murakoshi	et	al.,	1985;	Narici	&	Maffulli,	2010;	Tandler	&	Hoppel,	
1986).	Further,	we	show	mTORC1‐induced	mitochondrial	oxidative	
stress and catabolism is linked to the mTORC1‐dependent activation 
of	novel	STAT3‐GDF	signaling,	in	addition	to	the	previously	known	
FoxO	signaling	pathway.
It has been previously reported that sustained activation of 
mTORC1 inhibits autophagy and leads to late‐onset myopathy in a 
TSC1	null	mouse	model	(Castets	et	al.,	2013).	However,	the	mecha‐
nisms operant here appear to be complex and cannot be explained 
by impaired autophagy alone. Based on the evidence we present 
here	 of	 activated	 FoxO‐	 and	 GDFs‐mediated	 catabolic	 pathways,	
as	 well	 as	 the	 well‐known	 anabolic	 function	 of	 mTORC1	 (protein	
synthesis	 and	mitochondrial	 biogenesis;	 Saxton	&	 Sabatini,	 2017),	
we propose that the myopathy seen in mTORC1‐hyperactive mus‐
cle results from a complex process of anabolism and catabolism—
their imbalance ultimately leading to muscle fiber damage and loss 
(Figure	8f).	mTORC1	can	directly	activate	FoxO‐	and	GDF‐mediated	
catabolic signaling, independent of autophagy. mTORC1 directly 
phosphorylates	STAT3	at	 the	 serine	727	 site	 (Laplante	&	Sabatini,	
2013;	Wen	et	al.,	1995;	Yokogami	et	al.,	2000).	We	advance	this	ob‐
servation	by	demonstrating	that	activated	STAT3	regulates	GDF15	
at	the	transcriptional	level	through	binding	to	the	cis	DNA	element	
in	the	GDF15	promoter	sequence.	Therefore,	STAT3	is	a	novel	me‐
diator	situated	between	mTORC1’s	kinase	activity	and	GDF15	gene	
expression.	These	findings	link	mTORC1	to	the	GDF	family,	and	they	
add an additional catabolic signaling pathway, beyond the previously 
known	S6K‐Akt‐FoxO	feedback	pathway,	that	mediates	the	degen‐
erative	effect	of	mTORC1	(Figure	8f).
Interestingly,	 we	 show	 here	 also	 that	 GDF15	 itself	 facilitates	
autophagy by upregulating LC3. This seemingly contradictory reg‐
ulation may represent a cellular effort to maintain homeostasis in 
mTORC1‐activated	muscle.	Further,	abnormal	mitochondria	accumu‐
lation seen in the mTORC1‐activated muscles would seem unlikely to 
result solely from the inhibition of autophagy/passive accumulation. 
Active	mitochondrial	proliferation	induced	by	mTORC1	is	a	separate,	
important contributor to the observed mitochondrial accumula‐
tion	 (Cunningham	et	al.,	2007;	Koyanagi	et	al.,	2011;	Morita	et	al.,	
2013)	by	promoting	translation	of	mitochondria‐related	mRNAs	via	
F I G U R E  7  mTORC1‐activated	STAT3	transcriptionally	upregulates	GDF15.	(a)	mTORC1	activity	regulates	the	phosphorylation	of	STAT3	
in	mTORC1‐activated	muscle.	Western	blot	analysis	was	performed	with	TA	muscle	lysate.	n = 3, representative picture was shown. Note, 
mTORC1‐induced	STAT3	phosphorylation	is	suppressed	by	rapamycin	treatment.	(b)	mTORC1	activity	does	not	regulate	STAT3	mRNA	
levels.	Quantitative	PCR	was	performed	to	measure	mRNA	levels	in	gastrocnemius	muscle.	n	=	4	per	group.	(c)	STAT3	is	phosphorylated	
in	pS6+	muscle	fibers	in	aged	muscle.	Immunostaining	was	performed	to	detect	phosphorylated	S6	and	STAT3	(S727)	with	specific	
antibodies.	Arrowheads	indicate	positively	stained	muscle	fibers.	(d)	Inhibition	of	mTORC1	activity	suppresses	STAT3	phosphorylation	and	
the	expression	of	GDF15	in	cultured	myotubes.	Rapamycin,	2	nM,	for	24	hr.	Experiments	were	repeated	three	times,	and	representative	
images	were	shown.	(e	and	f)	Overexpression	of	STAT3	increases	the	expression	of	GDF15	in	vitro	and	in	vivo.	Constitutive	active	STAT	
(STAT3c)	was	transfected	into	C2C12	cells	(e)	or	electroporated	into	TA	muscle	(f).	GDF15	levels	were	examined	by	Western	blot	analysis.	
(g)	Inhibition	of	STAT3	activity	suppresses	the	expression	of	GDF15.	STAT3	inhibitor,	Stattic,	was	used	to	treat	cultured	myotubes	for	24	hr,	
and	GDF15	levels	were	examined	by	Western	blot	analysis.	Experiments	were	repeated	three	times	and	representative	image	was	shown.	
(h)	Silencing	STAT3	reduces	GDF15	expression.	siRNA	against	STAT3	was	transfected	into	C2C12	cells	and	RNA	was	harvested	4	days	later	
for	quantitative	PCR.	n	=	4,	*p	<	0.05.	(i,	j,	and	k)	STAT3	binds	to	GDF15	promoter.	Consensus	sequence	of	STAT3	binding	is	present	in	the	
promoter	sequence	of	GDF15	(i).	ChIP	assay	was	performed	with	STAT3	transfected	C2C12	cells	(j)	and	rapamycin‐treated	C2C12	myotubes	
(k).	n	=	4	each,	*p	<	0.05.	Increased	STAT3	level	increases	STAT3’s	DNA	binding,	whereas	rapamycin	treatment	reduces	STAT3	binding	to	the	
GDF	promoter
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inhibition	of	the	eukaryotic	translation	 initiation	factor	4E	(eIF4E)‐
binding	proteins	(4E‐BPs;	Morita	et	al.,	2013).
It is worth noting that although mTORC1 is hyperactive in all 
muscle fibers in the TSC1 ko mice, apoptotic changes were only 
sporadically seen by immunostaining for cleaved caspase 3. This 
was likely due to variation between cells in the intracellular bal‐
ance between oxidative stress and self‐defense/antioxidant 
systems from cell to cell. The negatively stained fibers may well 
become positive days/weeks later. Consistent with this hypoth‐
esis,	 the	 “few	apoptotic	 fibers”	 seen	at	9	months	old	 (Figure	3e)	
progresses	to	nearly	50%	fiber	loss	at	the	18	months	(Figure	2g).	
The accumulated damage over time is much more than the “few 
apoptotic fibers” seen early on. In addition, oxidative stress in‐
duced by hyperactive mTOR also leads to protein degradation, au‐
tophagy,	and	necrotic	changes	(Figure	8f).	In	these	cases,	the	fiber	
damage and death is not through the apoptotic pathway. In future 
studies, it might be possible to use laser microdissection to iso‐
late	out	the	pS6+	fibers	from	aging	muscle—this	would	allow	us	to	
study mTORC1‐related events in individual aging fiber in greater 
detail.
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mTORC1‐induced muscle fiber damage and loss appears to be a 
progressive process occurring over time. In TSC1 ko mice, the ele‐
vated mTORC1 activity does not cause a severe muscle degenera‐
tive phenotype until late adulthood, despite the fact that mTORC1 
has	 been	 activated	 since	 embryonic	 development.	We	 show	 also	
that oxidative stress and apoptosis‐related genes are significantly 
induced only at an older age. Similarly, in normal aging mice, acti‐
vation of mTORC1 in muscle fibers can be detected at middle age 
(12	months	old,	Supporting	 Information	Figure	S1),	but	we	saw	no	
significant	 degenerative	 morphology	 until	 30	months	 of	 age.	 We	
theorize that mTORC1‐induced mitochondrial enlargement/dys‐
function progresses until some turning point at which mitochondrial 
free‐radical	generation	(MOS)	overwhelms	resident	antioxidant	sys‐
tems, thereby causing catabolism. This framework implies that early 
preventive treatment via inhibition of mTORC1 signaling may in part 
prevent sarcopenia.
F I G U R E  8   Inhibition of mTORC1 
activity	in	aged	animals	inhibits	GDF15	
expression and prevents age‐related 
oxidative	stress	and	fiber	loss.	(a)	
Rapamycin	treatment	(14	ppm)	for	
~830 days beginning at age ~270 days 
suppresses muscle mTORC1 pathway 
activity,	STAT3	phosphorylation,	protein	
oxidation	(DNP),	cleaved	caspase	3,	
and	the	protein	expression	of	GDF15.	
Western	blot	analysis	was	performed	
with	specific	antibodies.	(b)	The	mRNA	
expression	levels	of	GDF3,	5,	and	
15	are	all	reduced	after	rapamycin	
treatment,	measured	by	quantitative	
PCR.	n	=	4,	*p	<	0.05.	(c)	Rapamycin	
treatment reduces aging‐induced protein 
carbonylation. Total muscle proteins were 
extracted from gastrocnemius muscle. 
The value for protein carbonylation is 
measured	by	ELISA	and	normalized	to	
the total protein input. n	=	4,	*p	<	0.05.	
(d)	Rapamycin	prevents	aging‐induced	
central	myonuclear	localization.	HE	
staining was performed and centrally 
located	nuclei	were	counted	in	TA	muscle.	
Representative images were shown, and 
abnormal fibers with centrally localized 
nuclei were indicated with arrow head. 
Results are percentage of cells with 
central nuclei over total fiber count. 200 
fibers counted per sample, n = 4 muscles, 
*p	<	0.05,	**p	<	0.01.	(e)	Age‐dependent	
loss of muscle fiber number is prevented 
by rapamycin treatment. Total number of 
muscle	fibers	in	TA	muscle	was	counted.	
Young: n = 4; old: n = 10; old with 
rapamycin: n	=	10,	*p	<	0.05.	(f)	Schematic	
diagram to show the hypothetical 
mechanism	underlying	mTORC1‐GDF‐
dependent muscle fiber loss during aging. 
Note, the signaling cascade linked by the 
green arrows was from in the current 
study, whereas the black dash line arrows 
from previous reports
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We	 tested	 this	 idea	 by	 treating	mice	with	 rapamycin	 (14	ppm)	
from the age of 270 days to the age of 900–1,099 days. The rapa‐
mycin	treatment	did	suppress	mTORC1	activity,	GDF15	expression,	
and	apoptosis,	and	prevent	fiber	loss	(Figure	8).	Additionally,	hyper‐
active mTORC1 increased the level of type I myosin heavy chain, but 
decreased	type	IIb,	in	TSC1	ko	mice	(Supporting	Information	Figure	
S10a).	 Inhibition	of	mTORC1	activity	with	 rapamycin	 in	aged	mus‐
cle	led	to	reduction	of	MHC	I	(Supporting	Information	Figure	S10b).	
Therefore, mTORC1 activity may also contribute to the age‐depen‐
dent conversion into slow oxidative fibers.
However,	the	protocol	of	rapamycin	treatment	that	we	used	in	
this study did not significantly rescue the age‐related decrease in 
muscle fiber size and wet weight, although there may be a trend in 
this	 direction	 (Supporting	 Information	 Figure	 S11).	 Although	 it	 is	
reasonable to speculate that this could be due to rapamycin inhib‐
iting the regenerative effort in aged muscle, the expression of em‐
bryonic	myosin	heavy	chain	(MyH3),	a	molecular	marker	of	muscle	
regeneration, was not altered significantly by rapamycin treatment 
(Supporting	Information	Figure	S12),	indicating	that	rapamycin	treat‐
ment, at least at this dosage, did not increase or decrease muscle 
regenerative	capacity.	We	suspect	that	long‐term,	continuous	treat‐
ment with rapamycin, as we used in this study, reduced the essential 
intracellular anabolic activity that is maintained by a basal level of 
mTORC1 in normal, healthy fibers during aging. This effect would 
compromise any potential beneficial effect of rapamycin. It is pos‐
sible that a different titration of the dose of rapamycin and/or an 
optimized	treatment	protocol	(e.g.,	intermittent	rather	than	contin‐
uous	duration,	shorter	duration	of	treatment)	might	result	 in	a	net	
muscle‐protective effect.
Growth	differentiation	factors	are	known	to	be	associated	with	
many	diseases	states.	For	example,	GDF15	plays	a	role	in	cancer	ca‐
chexia	 (Lerner	 et	 al.,	 2015;	Weide	et	 al.,	 2016),	mitochondrial	 dis‐
eases	(Kalko	et	al.,	2014;	Montero	et	al.,	2016;	Yatsuga	et	al.,	2015),	
and	as	a	mediator	of	intensive	care	unit	(ICU)‐acquired	muscle	weak‐
ness	 (Bloch	 et	 al.,	 2015).	 Its	 expression	 has	 even	 been	 associated	
with	mortality	(Wiklund	et	al.,	2010).	In	addition,	GDF15	regulates	
appetite and is related to weight loss and cancer‐related anorexia 
(Breit	et	al.,	2011;	Johnen	et	al.,	2007;	Lerner	et	al.,	2015;	Tsai	et	al.,	
2016,	2013,	2014;	Villars	et	al.,	2017),	likely	functioning	through	the	
receptors	of	the	previously	reported	TGF‐β	receptor	II	(Johnen	et	al.,	
2007)	and	the	recently	discovered	GFRAL	(GDNF	Family	Receptor	
Alpha	Like;	Emmerson	et	al.,	2017;	Hsu	et	al.,	2017;	Mullican	et	al.,	
2017;	 Yang	 et	 al.,	 2017)	 in	 the	 central	 nervous	 system.	 Anorexia	
could, of course, be a contributor to the loss of body weight in the 
mTORC1‐activated	mice	we	studied.	However,	it	is	unlikely	that	the	
mTORC1‐induced	muscle	damage	and	loss	is	entirely	due	to	GDF15‐
related	anorexia	because	(a)	mTORC1‐activated	muscle	reveals	a	het‐
erogeneous phenotype of muscle fibers with the presence of both 
the proliferated/enlarged and the degenerated/shrunken muscle fi‐
bers;	(b)	loss	of	the	skeletal	muscle	is	more	prominent	than	the	loss	
of	body	weight;	 (c)	GDFs	can	directly	 induce	catabolism	 in	muscle	
cells	in	vitro	and	in	vivo;	(d)	mTORC1	also	activates	FoxO‐mediated	
catabolic	pathways	through	inhibition	of	Akt,	as	previously	reported,	
independent	of	GDFs.	On	the	other	hand,	GDF15	has	also	been	re‐
ported also to have beneficial effects as an anti‐inflammatory and in 
a	protective	role	in	cardiac	muscle	(Kempf	et	al.,	2006,	2011).	High	
levels	of	circulating	GDF15	in	pregnant	women	(Moore	et	al.,	2000)	
appear harmful to neither their muscle nor overall health. It is thus 
likely	that	the	ultimate	effect	of	GDFs	is	context‐dependent.
The	catabolic	effect	of	GDF15	 in	 skeletal	muscle	 that	we	pro‐
pose	may	act	through	GFRAL	receptor	as	it	does	in	the	central	ner‐
vous	 system,	 since	GFRAL	 is	also	expressed	 in	cultured	myotubes	
and	 skeletal	muscle	 (Supporting	 Information	Figure	 S13).	 It	 is	 also	
possible	that	GDF3,	5,	and	15	regulate	muscle	catabolism	through	
an unknown intracellular mechanism, other than the ligand‐receptor 
interaction, which remains to be elucidated. Downstream effectors 
of	GDFs‐induced	oxidative	stress	and	catabolism	may	include	Smad3	
and	FoxO1,	 since	 these	 have	 been	 reported	 to	 compromise	mito‐
chondrial	function	and	induce	apoptosis	(Black	et	al.,	2007;	Jang	et	
al.,	2002;	Michaeloudes,	Sukkar,	Khorasani,	Bhavsar,	&	Chung,	2011;	
Wildey,	Patil,	&	Howe,	2003).	FoxO	is	also	able	to	induce	Bim	gene	
expression	 and	 apoptosis	 (McLoughlin	 et	 al.,	 2009;	 Shukla,	 Rizvi,	
Raisuddin,	 &	 Kakkar,	 2014).	 Our	 finding	 of	 GDF‐induced	 dephos‐
phorylation	of	FoxO	uncovers	a	novel	posttranslational	activation	of	
FoxO,	independent	of	Akt	activity	(Figure	6i).
Catabolism	induced	by	elevated	GDFs,	MOS,	and	activated	FoxO	
may lead directly to muscle fiber loss. It has been reported previously 
that dysfunctional mitochondria and apoptosis occur in aging skeletal 
muscle	(Bratic	&	Larsson,	2013;	Bua,	McKiernan,	Wanagat,	McKenzie,	
&	Aiken,	 2002;	 Chabi	 et	 al.,	 2008;	 Cheema	 et	 al.,	 2015;	Demontis	
et	al.,	2013;	Dirks	&	Leeuwenburgh,	2005;	Herbst,	Johnson,	Hynes,	
McKenzie,	&	Aiken,	2013;	Hiona	et	al.,	2010;	Jang	et	al.,	2010;	McArdle	
et	al.,	1999;	Pistilli,	Siu,	&	Alway,	2006;	Short	et	al.,	2005;	Stephen,	
Michael,	 &	 Parco,	 2011;	 Whitman,	 Wacker,	 Richmond,	 &	 Godard,	
2005),	 resulting	 in	apoptotic	 and	necrotic	 fiber	 loss	 (Cheema	et	al.,	
2015).	 Apoptotic	 muscle	 fiber	 death	 appears	 to	 be	 different	 from	
that in mononuclear cells because decay of an individual nucleus is 
insufficient	to	cause	death	of	multinucleated	muscle	fibers.	However,	
progressive, accumulated nuclear and cellular apoptotic changes may 
lead to gradual, perhaps segmental muscle fiber death over a long pe‐
riod	of	 time	 (e.g.,	 aging;	Cheema	et	al.,	2015;	Dupont‐Versteegden,	
2005).	GDFs	and	MOS	 increase	 free	 radicals,	 resulting	 in	oxidation	
and	 ubiquitination	 of	 cellular	 components,	 autophagy,	 and	 thereby	
ultimately	apoptotic	and/or	necrotic	cell	death.	Since	GDF3,	5,	and	
15	are	all	induced	by	mTORC1	and	since	they	functionally	overlap,	a	
muscle‐specific,	triple	knockout	of	GDF3,	5,	and	15	might	help	define	
GDFs’	unique	role	in	mTORC1‐induced	muscle	degeneration.
Lastly, it deserves mention that our findings are in some ways 
consistent	 with	 the	 “mitochondrial	 theory	 of	 aging”	 (Beckman	 &	
Ames,	1998;	Harman,	1972;	Miquel,	Economos,	Fleming,	&	Johnson,	
1980).	Our	mTORC1‐centric	view	advances	this	theory	by	identify‐
ing	mTORC1‐GDF	as	a	specific	inducer	of	MOS	in	the	aging	of	one	
particular	 tissue—skeletal	 muscle.	 Precisely	 how	 mTORC1	 is	 acti‐
vated in a subset of muscle fibers during aging remains unknown, 
but loss or damage of motor neuron during aging may contribute to 
mTORC1’s activation, since denervation indeed activates mTORC1 
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(Tang	 et	 al.,	 2014).	 IGF‐1,	 a	 conventional	 upstream	 regulator	 of	
mTORC1, however, does not regulate the serine 727 phosphoryla‐
tion	 and	 GDF15	 expression	 in	 cultured	 myotubes,	 indicating	 that	
GDF15	expression	 is	 regulated	by	 IGF/Akt‐independent	activation	
of	mTORC1	(Supporting	Information	Figure	S14).
In summary, we have discovered a novel molecular mecha‐
nism underlying age‐related muscle fiber damage and loss, linking 
mTORC1	with	GDFs,	and	we	suggest	that	mTORC1‐GDF	is	a	contrib‐
uting pathway to the development of sarcopenia. Cell damage and 
death	occurring	via	 this	mTORC1‐GDF	pathway	may	also	occur	 in	
other tissues during aging, since these genes are widely expressed.
4  | MATERIAL S AND METHODS
4.1 | Human latissimus dorsi and mouse muscle 
samples
Human	latissimus	dorsi	muscles	were	taken	during	thoracic	surgery	
with	approval	from	the	Stanford	Institutional	Review	Board.	Patients	
fasted for approximately 9 hr prior to the surgery and taking of biop‐
sies.	We	excluded	patients	with	more	than	mild	pulmonary	dysfunc‐
tion, cancer beyond stage I, or use of steroids of other drugs that 
can	affect	muscle	physiology.	Age	and	sex	are	shown	in	Supporting	
Information	Figure	S7.
The animal care and experimental procedures followed a protocol 
approved by the University of Michigan Committee on Use and Care 
of	Animals	and	the	University	of	California	San	Diego	Institutional	
Animal	 Care	 and	Use	 Committee.	 The	 generation	 of	 TSC1lox/lox	
mice	with	exons	17	and	18	of	Tsc1	flanked	by	loxP	sites	by	homol‐
ogous	recombination	was	done	as	described	previously	(Tang	et	al.,	
2014).	Mice	were	fed	with	regular	chow	and	water	ad	libitum.	TSC1	
ko and control animals were injected with rapamycin intraperitone‐
ally	(6	mg/kg	body	weight,	every	other	day)	for	8	weeks,	beginning	
at	 the	5	weeks	of	age.	Rapamycin	 (LC	Laboratories;	Woburn,	MA)	
was	dissolved	in	100%	ethanol,	stored	at	−20°C,	and	further	diluted	
in	an	aqueous	solution	of	5.2%	Tween	80	and	5.2%	PEG	400	(final	
ethanol	concentration,	2%)	immediately	before	use.	Hindlimb	mus‐
cles	were	collected	for	sample	analysis.	Fresh	muscle	tissues	from	
female	C57BL/6	mice	were	also	used	to	examine	the	expression	lev‐
els	of	protein	and	RNA	between	young	and	old.
HET3	 female	 mice	 were	 treated	 with	 rapamycin	 as	 described	
(Harrison	 et	 al.,	 2009;	 Miller	 et	 al.,	 2014).	 Treatment	 of	 rapamy‐
cin	 (14	ppm)	 started	 at	 270	days	 of	 age	 and	 evaluated	 at	 ~900–
1,096	days	 of	 age.	 Untreated,	 age‐matched,	 or	 young	 (2	months)	
mice	 were	 used	 as	 controls.	 Formalin‐fixed	muscle	 samples	 (UM‐
HET3)	were	used	for	histological	study.	Fresh	muscle	samples	(UT‐
HET3)	were	used	for	protein	and	RNA	analysis.
4.2 | Transcriptomic profiling of gene 
expression and data analysis
Total	 RNA	 was	 harvested	 from	 gastrocnemius	 muscle	 and	 sub‐
jected	to	Agilent	single	color	gene	microarray,	performed	by	the	
Human	 Immune	Monitoring	 Center	 at	 Stanford	University.	Data	
were	 normalized	 and	 analyzed	 using	 the	 GeneSpring	 GX	 and	
DAVID	 bioinformatics	 tools	 (http://david.ncifcrf.gov/content.
jsp?file=citation.htm).
4.3 | Gene transfection and electroporation
GDF15‐GFP	was	constructed	by	PCR	amplification	of	the	cDNA	of	
human	GDF15	and	ligation	into	the	pCMV6‐AC‐GFP	vector	between	
Sgf1 and Mlu1. The plasmid was transfected into cultured cells with 
lipofectamine	2000	(Invitrogen).	Electroporation	of	plasmid	into	tibi‐
alis	anterior	 (TA)	muscle	was	performed	as	previously	described17. 
Briefly,	two	hours	prior	to	electroporation,	TA	muscles	were	injected	
with	50	μl	of	hyaluronidase	(0.5	μ/μl,	Sigma‐Aldrich)	to	increase	the	
transfection	efficiency.	ECM830	electroporator	(BTX)	was	used	to	
deliver	eight	pulses	of	75	v/cm,	20‐ms	duration,	and	100‐ms	interval.	
Twenty	micrograms	of	plasmid	 (GDF15‐GFP	or	 control	GFP)	were	
electroporated	into	TA	muscles,	and	muscle	samples	were	harvested	
14	days	later	and	fixed	in	4%	paraformaldehyde	for	immunostaining.
C2C12	 cells	 were	 stably	 transfected	 with	 TSC1	 shRNA	 (open	
biosystems,	plko1	TSC1#217),	and	activated	mTORC1	activity	was	
confirmed	 by	 elevated	 pS6	 levels.	 GDF15	 siRNA	 was	 purchased	
from	 Santa	 Cruz	 Biotechnology.	 Twenty	 nM	 of	 control	 siRNA	 or	
GDF15	siRNA	was	transfected	to	TSC1	shRNA	stable	cell	 lines	for	
4	days,	followed	by	AV	and	PI	staining,	and	flow	cytometry.
4.4 | Flow cytometry
Flowcytometric	analysis	was	performed	by	standard	methods	with	
an	LSR	II	flow	cytometer	unit	(BD	biosciences).	Cells	were	digested	
and	 immunostaining	was	performed	with	Annexin	V	and	PI	 apop‐
tosis	detection	kits	 (BD	Biosciences).	After	staining,	the	cells	were	
filtered through a cell strainer and 100,000–1,000,000 events were 
acquired	for	each	sample.	Flow	cytometry	data	were	analyzed	with	
BD	FACSDiva	software.
4.5 | Western blotting analysis and real‐time PCR
Recombinant	 GDF3,	 5,	 and	 15	 were	 purchased	 from	 Biovision.	
Protein	expression	and	protein	phosphorylation	were	detected	by	
Western	 blotting	 analysis	 following	 standard	 procedures.	 Briefly,	
ten micrograms of total protein extracted from muscles was loaded 
onto	 4%–12%	 SDS‐PAGE	 gels	 and	 transferred	 to	 nitrocellulose	
membranes	 for	antibody	detection.	Antibodies	against	mouse	and	
human	GDF15	were	purchased	from	Santa	Cruz	Biotechnology,	Inc.	
The remainder of the antibodies was purchased from Cell Signaling 
Technology.	Antibodies	were	used	at	1:1,000	dilutions	for	Western	
blot	analysis.	Phosphorylation	sites	 that	 the	antibodies	can	 recog‐
nize	are:	pmTOR	(S2448),	pS6K1	(T389),	pS6	(S235/236),	pFoxO1/3	
(T24/T32),	 pFoxO1	 (S256),	 pSmad2	 (S465/467),	 pSmad3	 (S423/
S4250,	and	pSTAT3	(S727).
Gene	 expression	 levels	were	 detected	 by	 real‐time	 PCR.	 RNA	
was	 reverse‐transcribed	 with	 oligo	 (dT)	 primer	 and	 SuperScript	 II	
     |  17 of 20TANG eT Al.
(Invitrogen),	and	1/20	of	the	cDNA	mixture	served	as	template	for	
the	PCR	reactions.	Real‐time	PCR	was	performed	on	an	iCycler	(Bio‐
Rad,	Hercules,	CA)	by	using	SYBR	Green	SuperMix	(Bio‐Rad).
4.6 | Chromatin immunoprecipitation
Cultured	 C2C12	 cells	 were	 transfected	 with	 STAT3‐expressing	
plasmid, or differentiated into myotubes and treated with rapa‐
mycin	for	24	hr.	Cells	were	then	fixed	with	formaldehyde	(1%)	for	
10	min,	 followed	 by	 125	mM	 glycine	 for	 5	min.	 Cells	 were	 then	
washed,	 lysed,	 and	 centrifuged	at	950	g	 for	5	min	 to	 collect	 the	
nuclei. Nuclear lysate was sonicated to break down chromatin 
(~500	bp)	 and	 incubated	 with	 Protein	 A	 Agarose/salmon	 sperm	
DNA.	 After	 centrifugation,	 the	 supernatant	 (input	 DNA,	 an	 ali‐
quot	saved	for	measuring	input	DNA	amount)	was	incubated	with	
STAT3	antibody	and	IgG	(negative	control),	respectively,	overnight	
at	4°C,	and	then	added	with	Protein	A	Agarose	for	another	2	hr.	
This mixture was centrifuged at 220 g to precipitate the pro‐
tein–chromatin	 complex.	 After	 washing,	 the	 protein–chromatin	
complex	was	eluted	 from	Protein	A	Agarose,	 and	de‐crosslinked	
with	 NaCl	 (0.2	M)	 at	 65°C	 overnight.	 The	 protein–chromatin	
mixture	 was	 treated	 with	 proteinase	 K	 (0.2	mg/ml)	 at	 60°C	 for	
1 hr. The resulting mixture was further extracted with phenol/
chloroform	 for	 PCR	 amplification.	 Quantitative	 PCR	 was	 per‐
formed	with	primers	(Forward:	5′‐AAGGTCACATGGGACCGCGG;	
Reverse:	 5′‐TGCCCTGGGCGAGCTGCTGA).	 The	 amount	
of	 input	 DNA	 was	 measured	 by	 PCR	 with	 beta‐actin	 prim‐
ers	 (Forward:	 5′‐AGGCGGACTGTTACTGAGCTG;	 Reverse:	 5′‐
CAACCAACTGCTGTCGCCTT)	as	normalization	control.
4.7 | Muscle morphology, histology, 
immunostaining, SDH staining, DHE staining, and 
cross‐sectional area (CSA)
Muscle	samples	were	either	embedded	in	paraffin	(for	HE	staining)	
or	 freshly	 frozen	 (for	 SDH	 staining).	 Paraffin	 embedded	 samples	
were	sectioned	at	5	μm	thickness	for	standard	HE	staining.	Frozen	
muscle	 tissues	 (12	μm)	were	 sectioned	 on	 a	 Leica	 cryostat.	 Fresh	
sections	without	 fixation	were	used	 for	 SDH	staining,	while	 fresh	
sections	fixed	in	2%	paraformaldehyde	for	15	min	were	used	for	im‐
munostaining.	Antibodies	against	activated/cleaved	caspase	3	and	
pS6 were purchased from Cell Signaling and used at 1:100 dilutions. 
For	negative	control,	normal	serum	was	used	to	replace	primary	an‐
tibodies.	 Secondary	 antibodies	 (either	 anti‐rabbit,	 or	 anti‐mouse)	
conjugated	with	Cy5	or	FITC	were	used	at	1:500	dilution.
Succinate	dehydrogenase	 (SDH)	staining	was	performed	by	 in‐
cubating fresh muscle tissue sections in 0.1 M phosphate buffer, 
pH	7.6,	5	mM	EDTA,	pH	8.0,	1	mM	KCN,	21.8	mg/ml	 sodium	suc‐
cinate, and 1.24 mg/ml nitroblue tetrazolium for 20 min at room 
temperature. Sections were then rinsed, dehydrated, and mounted 
before microscopic visualization. Sections were observed using an 
Axiophot	 microscope	 (Carl	 Zeiss,	 Thornwood,	 NY)	 equipped	 with	
fluorescence optics.
Zeiss	LSM710	Laser	Scanning	microscope	and	Zen	software	sys‐
tem	(Carl	Zeiss)	were	used	to	take	confocal	images.
Dihydroethidium	(DHE)	staining	was	performed	on	snap‐frozen	
muscle	samples.	DHE	was	purchased	from	Invitrogen	and	reconsti‐
tuted	in	anhydrous	DMSO	(Sigma‐Aldrich)	at	a	stock	concentration	
at 10 mM. The staining solution was prepared fresh before use by 
1–1,000	dilution	of	the	stock	DHE	solution	with	1XPBS.	The	DHE/
PBS	solution	was	placed	over	cryosections	(20	μm)	and	incubated	for	
10 min in a dark chamber. The reaction was stopped by washing in 
1XPBS	three	times.	Slides	were	mounted	in	Prolong	Gold	antifading	
reagent	 (Invitrogen)	and	 imaged	by	 fluorescent	microscopy	 (Leica).	
The	cross‐sectional	area	(CSA)	was	measured	with	ImageJ	software	
after	taking	the	SDH‐stained	pictures.	No	less	than	500	fibers	were	
counted per specimen.
Total	muscle	fibers	in	TA	muscle	in	young,	old,	and	old	rapamycin‐
treated samples were counted. Cross sections of the same location 
of	each	muscle	were	created	and	stained	with	WGA.	Fiber	number	
was	counted	using	ImageJ	software.	In	TSC1	ko	muscle,	we	counted	
fibers specifically either from the lateral head of the gastrocnemius 
muscle	or	TA	muscle:	The	muscle	was	 sectioned	and	 stained	with	
WGA,	and	a	10X	image	was	then	taken	from	the	same	region,	of	the	
muscle.	All	fibers	in	this	one,	low‐power	field	from	this	region	were	
then counted. Results are presented as gross fiber counts.
One‐way	analysis	of	variance	 (ANOVA)	was	used	to	determine	
significance when there were more than three groups for compar‐
ison,	followed	by	Tukey	post	hoc	test.	Student's	t‐test was used to 
evaluate the statistical significance between two groups. p	<	0.05	
was considered as statistically significant.
4.8 | Transmission electron microscopy
Mice were anesthetized by intraperitoneal injection of ketamine 
(100	mg/kg)	 and	 xylazine	 (10	mg/kg)	 and	 then	 perfused	 via	 car‐
diac	puncture	with	4%	paraformaldehyde	(PFA)	in	0.1	M	cacodylate	
buffer,	 pH	 7.4.	 Soleus	muscles	 from	 the	wild‐type	 and	 the	 TSC−/− 
mice were isolated and immersed in the same fixative for 24 hr at 
4°C.	Muscles	were	then	fixed	in	1.5%	glutaraldehyde,	3%	PFA,	5%	
sucrose	in	0.1	M	cacodylate	buffer,	pH	7.4,	at	room	temperature	for	
2	hr.	The	samples	were	postfixed	in	1%	OsO4	in	the	same	buffer	for	
1 hr, stained en bloc	 in	2%	uranyl	 acetate	 in	10%	ethanol	 for	1	hr,	
dehydrated	 in	 ethanol,	 and	 embedded	 in	 LX112.	 Tissue	 sections	
were stained with uranyl acetate and lead citrate and examined in a 
Jeol	JEM	1200EX	II	electron	microscope	(JEOL	USA,	Peabody,	MA).	
Magnification is indicated on each image.
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